# Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

> **NCT07225972** · PHASE3 · NOT_YET_RECRUITING · sponsor: **New York Medical College** · enrollment: 69 (estimated)

## Conditions studied

- CMV
- AdV Infection
- AdV Reactivation
- Adenovirus
- Cytomegalovirus Infections

## Interventions

- **DRUG:** Standard of Care Antiviral medications
- **BIOLOGICAL:** Viral CTLs

## Key facts

- **NCT ID:** NCT07225972
- **Lead sponsor:** New York Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2031-12-01
- **Final completion:** 2032-12-01
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07225972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07225972, "Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07225972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*